Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Pharmaceutics|June 28, 2023
Development of a Gene and Nucleic Acid Delivery System for Skeletal Muscle Administration via Limb Perfusion Using Nanobubbles and UltrasoundShohko Sekine, Sayaka Mayama, Nobuaki Nishijima, et al.
Carcinogenesis|January 12, 2010
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypesTakashi Kohno, Hideo Kunitoh, Yoko Shimada, et al.
Cancer Research|November 15, 2011
Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomasHirokazu Okayama, Takashi Kohno, Yuko Ishii, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 26, 2014
Necklace cytoplasmic bodies in hereditary myopathy with early respiratory failureAkinori Uruha, Yukiko K Hayashi, Yasushi Oya, et al.
The Oncologist|June 3, 2026
Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial DesignsHillary Andrews, Raja Agnihotram, Gideon Blumenthal, et al.
Cancer Science|May 21, 2026
Neutrophil-Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo-ImmunotherapyKeita H Nagaoka, Hiroki Yamashita, Chiaki Mashima, et al.
Cancer Science|May 21, 2026
A cDC1-NK/T-Malignant Cell Circuit Drives Immunogenic Remodeling Under PD-1 Blockade in Gastric CancerTakuya Nakatsuru, Hiroki Yamashita, Chiaki Mashima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell CarcinomaNizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Pageof 5